Early Post-Transplant Serum Ferritin Levels Predict Survivals in Recipients of Haploidentical Stem Cell Transplantation Using PTCY as GVHD Prophylaxis.
Fiche publication
Date publication
juillet 2021
Journal
Transplantation and cellular therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Dr DAGUINDAU Etienne
Tous les auteurs :
Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Gouill SL, Béné MC, Chevallier P
Lien Pubmed
Résumé
The negative impact of high serum ferritin levels (SFL) before and after allogeneic hematopoietic cell transplantation (Allo-SCT) on outcomes is well recognized. However, it is ill-documented in adults receiving haploidentical SCT (Haplo-SCT) with post-transplant cyclophosphamide (PTCY) for hematological malignancies.
Mots clés
DRI, PTCY, age, allogeneic stem cell transplantation, ferritin, haploidentical
Référence
Transplant Cell Ther. 2021 Jul 7;: